胃康Ⅰ号方治疗中虚气逆型反流性食管炎临床观察

Observation on Reflux Esophagitis of Middle Deficiency and Qi Rebellion Treated with Weikang Ⅰ Formula

目的 ：观察胃康Ⅰ号方联合雷贝拉唑钠肠溶胶囊对中虚气逆型反流性食管炎（RE）患者的临床疗效。方法 ：采用随机数字表法将60例RE患者分为对照组和治疗组各30例,对照组予雷贝拉唑钠肠溶胶囊,每次20 mg,早晚各一次;治疗组在对照组基础上加用胃康Ⅰ号方,每日1剂,疗程均为8周,分别观察两组疗效。结果：治疗组临床疗效、胃镜下炎症疗效均优于对照组,两组比较差异有统计学意义（P〈0.05）;治疗组中医症候积分、Gerd Q积分均明显低于对照组（P〈0.01）;随访6个月治疗组复发率21.4%,明显低于对照组52.4%（P〈0.05）。结论：胃康1号方联合雷贝拉唑钠肠溶胶囊治疗RE疗效好,能明显缓解临床症状,降低复发率。

Objective：To observe the clinical efficacy of Weikang Ⅰ formula combined rabeprazole sodium enteric-coated capsule on reflux esophagitis（RE） of middle deficiency and qi rebellion type. Method ：Sixty patients with RE were randomly divided into the control group and the treatment group,30 cases in each group by a random number table. Patients in both two groups were given rabeprazole sodium enteric-coated capsule 20 mg in the morning and evening,and patients in the treatment group was also given Weikang Ⅰformula,1 dose Ya day. In the two groups,the treatment lasted for 8 weeks and the clinical efficacy was observed. Results：The clinical effect of syndromes and the effect on inflammation under gastroscopy in the treatment group were better than those in the control group,with statistical difference（P〈0.05）. The treatment group was lower than the control group on the traditional Chinese medicine symptom score,Gerd Q score,with significant difference（P〈0.01）. At 6-month follow-up,the recurrence rate in the treatment group was21.4% and was significantly lower than that in the control group 52.4%（P〈0.05）. Conclusion：Weikang Ⅰformula combined with rabeprazole sodium enteric-coated capsule showed better curative effect for RE. It could alleviate the clinical symptom and reduce the recurrence rate.